DNA nanoparticle-mediated ABCA4 delivery rescues Stargardt dystrophy in mice
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Mutations in the photoreceptor-specific flippase ABCA4 are associated with Stargardt disease and many other forms of retinal degeneration that currently lack curative therapies. Gene replacement is a logical strategy for ABCA4-associated disease, particularly given the current success of traditional viral-mediated gene delivery, such as with adeno-associated viral (AAV) vectors. However, the large size of the ABCA4 cDNA (6.8 kbp) has hampered progress in the development of genetic treatments. Nonviral DNA nanoparticles (NPs) can accommodate large genes, unlike traditional viral vectors, which have capacity limitations. We utilized an optimized DNA NP technology to subretinally deliver ABCA4 to Abca4-deficient mice. We detected persistent ABCA4 transgene expression for up to 8 months after injection and found marked correction of functional and structural Stargardt phenotypes, such as improved recovery of dark adaptation and reduced lipofuscin granules. These data suggest that DNA NPs may be an excellent, clinically relevant gene delivery approach for genes too large for traditional viral vectors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Outstanding studies from Naash and colleagues showed that rod-shaped CK30-PEG (polyethylene glycol)-compacted NPs effectively transfected both RPE and photoreceptors and showed efficacious gene therapy of Rpe65−/− (retinal pigment epithelium 65; model of LCA) and Abca4−/− (Stargardt Disease) mice [39,40,41].”
From The Ocular Gene Delivery Landscape (2021) · cites this paper as [39]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Generally, these methods carry low risk of immune responses commonly associated with viral delivery [44,63,64].”
From Viral Delivery Systems for CRISPR (2019) · cites this paper as [63]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Single-molecule DNA nanoparticles compacted by polyethylene glycol (PEG)-substituted lysine peptides (CK30-PEG) have been used to carry payloads up to 20 kb in size,82,83 with several groups demonstrating their safety in BALB/c mice and rds+/− Rho-/- or Abca4-/- mouse models of retinal degeneration.82–86”
From Gene Therapy for Retinal Degenerative Diseases: Progress, Challenges, and Future Directions (2023) · cites this paper as [86]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Weng, J., Mata, N. L., Azarian, S. M., Tzekov, R. T., Birch, D. G., & Travis, G. H. (1999) · Cell · doi:10.1016/s0092-8674(00)80602-9 · Cited by 881 · cited 1×
“Given the packaging capacity of our NPs, we evaluated whether they could express the large ABCA4 therapeutic gene and mediate improvement in a Stargardt disease model (15).”
Konstan, M. W., Davis, P. B., Wagener, J. S., Hilliard, K. A., Stern, R. C., Milgram, L. J. H., Kowalczyk, T. H., Hyatt, S. L., Fink, T. L., Gedeon, C. R., et al. (2004) · Human Gene Therapy · doi:10.1089/hum.2004.15.1255 · Cited by 298
Self-citationAllocca, M., Doria, M., Petrillo, M., Colella, P., Garcia-Hoyos, M., Gibbs, D., Kim, S. R., Maguire, A., Rex, T. S., Di Vicino, U., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34316 · Cited by 292 · cited 1×
“(12); however, subsequent reports demonstrated that the AAVs employed contained a heterogenous mix of DNA, not intact ABCA4 expression cassettes (13).”
Kong, J., Kim, S.-R., Binley, K., Pata, I., Doi, K., Mannik, J., Zernant-Rajang, J., Kan, O., Iqball, S., Naylor, S., et al. (2008) · Gene Therapy · doi:10.1038/gt.2008.78 · Cited by 215
Biochemical defects in ABCR protein variants associated with human retinopathies
Sun, H., Smallwood, P. M., & Nathans, J. (2000) · Nature Genetics · doi:10.1038/79994 · Cited by 203
Nanoparticles of Compacted DNA Transfect Postmitotic Cells
Liu, G., Li, D., Pasumarthy, M. K., Kowalczyk, T. H., Gedeon, C. R., Hyatt, S. L., Payne, J. M., Miller, T. J., Brunovskis, P., Fink, T. L., et al. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305776200 · Cited by 190
Self-citationTransfection of airway epithelium by stable PEGylated poly-l-lysine DNA nanoparticles in vivo
Ziady, A.-G., Gedeon, C. R., Miller, T., Quan, W., Payne, J. M., Hyatt, S. L., Fink, T. L., Muhammad, O., Oette, S., Kowalczyk, T., et al. (2003) · Molecular Therapy · doi:10.1016/j.ymthe.2003.07.007 · Cited by 165
Self-citationFink, T. L., Klepcyk, P. J., Oette, S. M., Gedeon, C. R., Hyatt, S. L., Kowalczyk, T. H., Moen, R. C., & Cooper, M. J. (2006) · Gene Therapy · doi:10.1038/sj.gt.3302761 · Cited by 139 · cited 1×
“Studies using luciferase reporter vectors ranging in size from 5.3 to 20.2 kbp (generated by introducing λ -bacteriophage DNA fragments into the parent plasmid) demonstrated comparable gene expression regardless of vector size, suggesting that these NPs could deliver large genes (10).”
InfluentialSelf-citationCai, X., Conley, S. M., Nash, Z., Fliesler, S. J., Cooper, M. J., & Naash, M. I. (2010) · The FASEB Journal · doi:10.1096/fj.09-139147 · Cited by 120
Self-citationCai, X., Nash, Z., Conley, S. M., Fliesler, S. J., Cooper, M. J., & Naash, M. I. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005290 · Cited by 109 · cited 3×
“They have recently been used to mediate phenotypic rescue in rodent models of retinitis pig-mentosa, Parkinson disease, and cystic fibrosis, and were safely employed in a phase I/II clinical trial for cystic fibrosis (2, 8, 9).”
Self-citationMolday, R. (2007) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-007-9118-6 · Cited by 97
Minimal toxicity of stabilized compacted DNA nanoparticles in the murine lung
Ziady, A.-G., Gedeon, C. R., Muhammad, O., Stillwell, V., Oette, S. M., Fink, T. L., Quan, W., Kowalczyk, T. H., Hyatt, S. L., Payne, J., et al. (2003) · Molecular Therapy · doi:10.1016/j.ymthe.2003.09.002 · Cited by 93
Self-citationLittle Vector, Big Gene Transduction: Fragmented Genome Reassembly of Adeno-associated Virus
Hirsch, M. L., Agbandje-McKenna, M., & Jude Samulski, R. (2010) · Molecular Therapy · doi:10.1038/mt.2009.280 · Cited by 85
Long-term Transgene Expression in the Central Nervous System Using DNA Nanoparticles
Yurek, D. M., Fletcher, A. M., Smith, G. M., Seroogy, K. B., Ziady, A. G., Molter, J., Kowalczyk, T. H., Padegimas, L., & Cooper, M. J. (2009) · Molecular Therapy · doi:10.1038/mt.2009.2 · Cited by 79
Self-citationPhotoreceptor Cell Degeneration in Abcr –/– Mice
Wu, L., Nagasaki, T., & Sparrow, J. R. (2010) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4419-1399-9_61 · Cited by 77
Yurek, D. M., Flectcher, A. M., Kowalczyk, T. H., Padegimas, L., & Cooper, M. J. (2009) · Cell Transplantation · doi:10.3727/096368909x12483162196881 · Cited by 73
Self-citationConley, S. M., Cai, X., Makkia, R., Wu, Y., Sparrow, J. R., & Naash, M. I. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.10.007 · Cited by 54
Self-citationHan, Z., Koirala, A., Makkia, R., Cooper, M. J., & Naash, M. I. (2012) · Nanomedicine · doi:10.2217/nnm.11.158 · Cited by 41
Self-citationGlushakova, L. G., Timmers, A. M., Issa, T., Cortez, N. G., Pang, J., Teusner, J. T., & Hauswirth, W. W. (2006) · PubMed · Cited by 19
Research works printed but not linked: 1
- Glushakova, 2006, Mol Vis., 12, 298
Cited by
Cremers, F. P. M., Lee, W., Collin, R. W. J., & Allikmets, R. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100861 · Cited by 315
Role of ABC transporters in lipid transport and human disease
Tarling, E. J., Vallim, T. Q. D. A., & Edwards, P. A. (2013) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2013.01.006 · Cited by 301
Viral Delivery Systems for CRISPR
Xu, C. L., Ruan, M. Z. C., Mahajan, V. B., & Tsang, S. H. (2019) · Viruses · doi:10.3390/v11010028 · Cited by 277
“Generally, these methods carry low risk of immune responses commonly associated with viral delivery [44,63,64].”
BackgroundEffective delivery of large genes to the retina by dual AAV vectors
Trapani, I., Colella, P., Sommella, A., Iodice, C., Cesi, G., de Simone, S., Marrocco, E., Rossi, S., Giunti, M., Palfi, A., et al. (2014) · EMBO Molecular Medicine · doi:10.1002/emmm.201302948 · Cited by 269
A comprehensive review of retinal gene therapy
Boye, S. E., Boye, S. L., Lewin, A. S., & Hauswirth, W. W. (2013) · Molecular Therapy · doi:10.1038/mt.2012.280 · Cited by 262
Metadata
- Authors
- Han, Z., Conley, S. M., Makkia, R. S., Cooper, M. J., & Naash, M. I.
- Affiliations
- University of Oklahoma Health Sciences Center (US)
- University of Oklahoma (US)
- Copernicus Therapeutics (United States) (US)
- Corresponding author
- Naash, Muna I.
- Venue
- Journal of Clinical Investigation
- Published
- 2012-09-04
- Volume
- 122
- Issue
- 9
- Pages
- 3221-3226
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC3428101
- OpenAlex
- W2055017226
- Cited by
- 150
- References
- 19
- Citations by year
- 2026: 5 · 2025: 5 · 2024: 6 · 2023: 10 · 2022: 5 · 2021: 21 · 2020: 11 · 2019: 9 · 2018: 10 · 2017: 10 · 2016: 9 · 2015: 18 · 2014: 15 · 2013: 15 · 2012: 1
- FWCI
- 6.29
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Foundation Fighting Blindness
- University of Oklahoma
- National Institutes of Health
- University of Oklahoma Health Sciences Center
- National Eye Institute (R01EY018656, R01EY022778, R01EY010609)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Keywords
- DNA nanoparticles, ABCA4, Stargardt disease, gene replacement therapy, non-viral gene delivery, subretinal injection, retinal degeneration, photoreceptors, lipofuscin granules, dark adaptation
- MeSH terms
- Analysis of Variance, Animals, Corneal Dystrophies, Hereditary, DNA, Humans, Lipofuscin, Mice, Inbred C57BL, Phenotype, Genetic Therapy, Gene Expression, Mice, Knockout, ATP-Binding Cassette Transporters, Transgenes, Mice, Nanoparticles, Retinal Pigment Epithelium, Injections, Intraocular
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.